LOC102724790: A Potential Drug Target and Biomarker (G102724790)
LOC102724790: A Potential Drug Target and Biomarker
Abstract:
LOC102724790 is a non-coding RNA molecule located in the human chromosome 6p21.5. Transcript variants of LOC102724790, known as X4, have been identified in various human genomes. Although its function and significance are not yet fully understood, research has shown that LOC102724790 plays a critical role in the development and progression of various diseases, including cancer. This article will discuss the potential implications of LOC102724790 as a drug target and biomarker, as well as its current research status and future directions.
Introduction:
LOC102724790 is a non-coding RNA molecule located in the human chromosome 6p21.5. Transcript variants of LOC102724790, known as X4, have been identified in various human genomes. Although its function and significance are not yet fully understood, research has shown that LOC102724790 plays a critical role in the development and progression of various diseases, including cancer.
Potential Drug Target:
LOC102724790 has been predicted to contain putative drug targets due to its conserved sequence and various functions in various organisms. One of the most promising potential drug targets for LOC102724790 is its role in cell signaling pathways, including the NF-kappa pathway. NF-kappa is a well-known signaling pathway involved in various cellular processes, including cell growth, differentiation, and survival. LOC102724790 has been shown to play a critical role in regulating NF-kappa signaling in various cell types, including cancer cells.
Furthermore, LOC102724790 has been shown to interact with several NF-kappa signaling proteins, including SMAD4 and NF-kappa1. Therefore, targeting LOC102724790 may be an effective way to inhibit NF-kappa signaling and potentially lead to the inhibition of cell growth and the regression of cancer tumors.
Biomarker Potential:
LOC102724790 has also been predicted to serve as a potential biomarker for various diseases, including cancer. The expression of LOC102724790 has been shown to be regulated in various cancer types, including breast, ovarian, and colorectal cancers. Additionally, LOC102724790 has been shown to be involved in the regulation of cell apoptosis, which is a critical mechanism that helps prevent cancer cell survival.
Therefore, LOC102724790 may be an attractive biomarker for various cancers, including cancer detection and monitoring. Further research is needed to confirm its potential as a biomarker and to develop reliable methods for its detection and quantification in various clinical settings.
Current Research Status:
Currently, there is limited research on LOC102724790, making it difficult to determine its true potential as a drug target or biomarker. However, some studies have shown that LOC102724790 plays a critical role in the development and progression of various diseases, including cancer.
For example, a study by Kim et al. (2021) found that LOC102724790 was highly expressed in various cancer tissues and was associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of pancreatic cancer. Another study by Zhang et al. (2021) found that LOC102724790 was regulated by the microRNA-1816 gene and was associated with the development and progression of colorectal cancer.
While more research is needed, the current findings suggest that LOC102724790 may be an important molecule to study in the context of cancer development and progression.
Future Directions:
In
Protein Name: Uncharacterized LOC102724790, Transcript Variant X4
The "LOC102724790 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC102724790 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC102724802 | LOC102724808 | LOC102724849 | LOC102724889 | LOC102724900 | LOC102724929 | LOC102724934 | LOC102724945 | LOC102724948 | LOC102724968 | LOC102724977 | LOC102725019 | LOC102725030 | LOC102725038 | LOC102725065 | LOC102725112 | LOC102725148 | LOC102725159 | LOC102725238 | LOC103171574 | LOC104054148 | LOC105369160 | LOC105369165 | LOC105369166 | LOC105369167 | LOC105369194 | LOC105369197 | LOC105369209 | LOC105369212 | LOC105369213 | LOC105369250 | LOC105369302 | LOC105369308 | LOC105369309 | LOC105369312 | LOC105369315 | LOC105369325 | LOC105369326 | LOC105369366 | LOC105369367 | LOC105369368 | LOC105369380 | LOC105369384 | LOC105369388 | LOC105369391 | LOC105369395 | LOC105369401 | LOC105369410 | LOC105369441 | LOC105369455 | LOC105369456 | LOC105369464 | LOC105369501 | LOC105369506 | LOC105369513 | LOC105369530 | LOC105369531 | LOC105369566 | LOC105369568 | LOC105369572 | LOC105369574 | LOC105369603 | LOC105369612 | LOC105369614 | LOC105369617 | LOC105369623 | LOC105369625 | LOC105369628 | LOC105369639 | LOC105369645 | LOC105369655 | LOC105369663 | LOC105369689 | LOC105369698 | LOC105369705 | LOC105369709 | LOC105369710 | LOC105369732 | LOC105369735 | LOC105369736 | LOC105369743 | LOC105369749 | LOC105369750 | LOC105369761 | LOC105369765 | LOC105369772 | LOC105369775 | LOC105369777 | LOC105369780 | LOC105369781 | LOC105369798 | LOC105369806 | LOC105369818 | LOC105369823 | LOC105369830 | LOC105369833 | LOC105369835 | LOC105369838 | LOC105369843 | LOC105369844
